FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803100812> ?p ?o ?g. }

• W2803100812 endingPage "1287" @default.
• W2803100812 startingPage "1278" @default.
• W2803100812 abstract "Essentials Net benefit of venous thromboprophylaxis (VTE) in patients hospitalized for infections is unknown. MAGELLAN trial subgroup analysis was performed for patients hospitalized for acute infectious diseases. At day 35, prolonged rivaroxaban prophylaxis reduced VTE compared to enoxaparin (4.2% vs. 6.6%). Rivaroxaban prophylaxis reduced VTE in patients hospitalized for active lung infections.Background Despite the well-established association between infection and venous thromboembolism (VTE), there are few data specifically assessing the efficacy and safety of the VTE prophylaxis strategies for patients hospitalized for acute infectious diseases. Objectives To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days. Patients/Methods A subgroup analysis of patients hospitalized for acute infectious diseases in the MAGELLAN trial was performed. The primary efficacy outcome was the composite of asymptomatic proximal or symptomatic VTE at days 10 and 35. The principal safety outcome was the composite of major or clinically relevant non-major bleeding. Results Three thousand one hundred and seventy-three patients with acute infectious diseases leading to hospitalization were randomized to either rivaroxaban (n = 1585) or enoxaparin/placebo (n = 1588), and received at least one dose of study medication. At day 10, primary composite efficacy outcomes did not differ between prophylaxis strategies (rivaroxaban, 2.7%; and enoxaparin, 3.7%). At day 35, there were fewer VTE events with rivaroxaban (4.2%) than with enoxaparin (6.6%) (relative risk [RR] 0.64; 95% confidence interval [CI] 0.45-0.92). Patients with pulmonary infections randomized to rivaroxaban had a lower incidence of VTE both at 10 days (RR 0.50, 95% CI 0.28-0.90) and at 35 days (RR 0.54, 95% CI 0.33-0.87). Primary safety outcome events were increased with rivaroxaban (RR 2.42, 95% CI 1.60-3.66). Conclusions Prolonged rivaroxaban prophylaxis reduced the incidence of VTE in patients hospitalized for acute infectious diseases, particularly those involving the lungs. Efficacy benefits were, in part, offset by bleeding outcomes. ClinicalTrials.gov Number: NCT 00571649." @default.
• W2803100812 created "2018-05-17" @default.
• W2803100812 creator A5023161395 @default.
• W2803100812 creator A5050586204 @default.
• W2803100812 creator A5051784294 @default.
• W2803100812 creator A5067121007 @default.
• W2803100812 creator A5088471251 @default.
• W2803100812 date "2018-07-01" @default.
• W2803100812 modified "2023-10-17" @default.
• W2803100812 title "Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study" @default.
• W2803100812 cites W1484074550 @default.
• W2803100812 cites W1501123671 @default.
• W2803100812 cites W1516067462 @default.
• W2803100812 cites W1602299201 @default.
• W2803100812 cites W1967273209 @default.
• W2803100812 cites W1975704243 @default.
• W2803100812 cites W1979838917 @default.
• W2803100812 cites W1989528047 @default.
• W2803100812 cites W1996767141 @default.
• W2803100812 cites W1997891243 @default.
• W2803100812 cites W2010055392 @default.
• W2803100812 cites W2045321169 @default.
• W2803100812 cites W2045819100 @default.
• W2803100812 cites W2052960256 @default.
• W2803100812 cites W2065276135 @default.
• W2803100812 cites W2083658263 @default.
• W2803100812 cites W2085481595 @default.
• W2803100812 cites W2095377565 @default.
• W2803100812 cites W2106296789 @default.
• W2803100812 cites W2110992040 @default.
• W2803100812 cites W2118615533 @default.
• W2803100812 cites W2125568432 @default.
• W2803100812 cites W2126794053 @default.
• W2803100812 cites W2129314932 @default.
• W2803100812 cites W2134923719 @default.
• W2803100812 cites W2159407715 @default.
• W2803100812 cites W2159520495 @default.
• W2803100812 cites W2169493096 @default.
• W2803100812 cites W2170663692 @default.
• W2803100812 cites W2170708401 @default.
• W2803100812 cites W2170952317 @default.
• W2803100812 cites W2172191543 @default.
• W2803100812 cites W2313177501 @default.
• W2803100812 cites W2465426327 @default.
• W2803100812 cites W2613641110 @default.
• W2803100812 cites W2762014638 @default.
• W2803100812 cites W2989714602 @default.
• W2803100812 doi "https://doi.org/10.1111/jth.14146" @default.
• W2803100812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29753308" @default.
• W2803100812 hasPublicationYear "2018" @default.
• W2803100812 type Work @default.
• W2803100812 sameAs 2803100812 @default.
• W2803100812 citedByCount "24" @default.
• W2803100812 countsByYear W28031008122020 @default.
• W2803100812 countsByYear W28031008122021 @default.
• W2803100812 countsByYear W28031008122022 @default.
• W2803100812 countsByYear W28031008122023 @default.
• W2803100812 crossrefType "journal-article" @default.
• W2803100812 hasAuthorship W2803100812A5023161395 @default.
• W2803100812 hasAuthorship W2803100812A5050586204 @default.
• W2803100812 hasAuthorship W2803100812A5051784294 @default.
• W2803100812 hasAuthorship W2803100812A5067121007 @default.
• W2803100812 hasAuthorship W2803100812A5088471251 @default.
• W2803100812 hasBestOaLocation W28031008121 @default.
• W2803100812 hasConcept C120665830 @default.
• W2803100812 hasConcept C121332964 @default.
• W2803100812 hasConcept C126322002 @default.
• W2803100812 hasConcept C142724271 @default.
• W2803100812 hasConcept C168563851 @default.
• W2803100812 hasConcept C187960798 @default.
• W2803100812 hasConcept C204787440 @default.
• W2803100812 hasConcept C27081682 @default.
• W2803100812 hasConcept C2776301958 @default.
• W2803100812 hasConcept C2778661090 @default.
• W2803100812 hasConcept C2779161974 @default.
• W2803100812 hasConcept C44249647 @default.
• W2803100812 hasConcept C61511704 @default.
• W2803100812 hasConcept C71924100 @default.
• W2803100812 hasConceptScore W2803100812C120665830 @default.
• W2803100812 hasConceptScore W2803100812C121332964 @default.
• W2803100812 hasConceptScore W2803100812C126322002 @default.
• W2803100812 hasConceptScore W2803100812C142724271 @default.
• W2803100812 hasConceptScore W2803100812C168563851 @default.
• W2803100812 hasConceptScore W2803100812C187960798 @default.
• W2803100812 hasConceptScore W2803100812C204787440 @default.
• W2803100812 hasConceptScore W2803100812C27081682 @default.
• W2803100812 hasConceptScore W2803100812C2776301958 @default.
• W2803100812 hasConceptScore W2803100812C2778661090 @default.
• W2803100812 hasConceptScore W2803100812C2779161974 @default.
• W2803100812 hasConceptScore W2803100812C44249647 @default.
• W2803100812 hasConceptScore W2803100812C61511704 @default.
• W2803100812 hasConceptScore W2803100812C71924100 @default.
• W2803100812 hasFunder F4320309464 @default.
• W2803100812 hasFunder F4320337415 @default.
• W2803100812 hasIssue "7" @default.
• W2803100812 hasLocation W28031008121 @default.
• W2803100812 hasLocation W28031008122 @default.
• W2803100812 hasOpenAccess W2803100812 @default.

• next